Enanta Pharmaceuticals (NASDAQ:ENTA) Share Price Crosses Below 200-Day Moving Average of $13.04

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)’s stock price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $13.04 and traded as low as $12.78. Enanta Pharmaceuticals shares last traded at $13.45, with a volume of 78,288 shares.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on ENTA. StockNews.com raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 8th. HC Wainwright reduced their price target on Enanta Pharmaceuticals from $28.00 to $27.00 and set a “buy” rating for the company in a report on Tuesday, May 7th. Finally, JMP Securities dropped their price target on shares of Enanta Pharmaceuticals from $23.00 to $22.00 and set a “market outperform” rating on the stock in a research note on Tuesday, May 7th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, Enanta Pharmaceuticals presently has an average rating of “Hold” and an average price target of $19.00.

Enanta Pharmaceuticals Price Performance

The firm has a 50-day moving average of $12.73 and a 200 day moving average of $13.04. The company has a market capitalization of $284.87 million, a PE ratio of -2.16 and a beta of 0.60.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Monday, May 6th. The biotechnology company reported ($1.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.21). Enanta Pharmaceuticals had a negative net margin of 180.76% and a negative return on equity of 64.85%. The company had revenue of $17.05 million for the quarter, compared to analysts’ expectations of $16.47 million. Equities analysts expect that Enanta Pharmaceuticals, Inc. will post -5.95 EPS for the current year.

Insider Activity at Enanta Pharmaceuticals

In related news, insider Tara Lynn Kieffer sold 7,266 shares of the firm’s stock in a transaction on Monday, June 17th. The stock was sold at an average price of $12.33, for a total value of $89,589.78. Following the transaction, the insider now directly owns 32,341 shares of the company’s stock, valued at approximately $398,764.53. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 13.64% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Laurion Capital Management LP purchased a new stake in shares of Enanta Pharmaceuticals during the third quarter worth about $126,000. Krensavage Asset Management LLC raised its position in shares of Enanta Pharmaceuticals by 6.9% during the third quarter. Krensavage Asset Management LLC now owns 735,103 shares of the biotechnology company’s stock valued at $8,211,000 after buying an additional 47,490 shares during the last quarter. Walleye Capital LLC lifted its holdings in shares of Enanta Pharmaceuticals by 342.8% in the third quarter. Walleye Capital LLC now owns 119,364 shares of the biotechnology company’s stock worth $1,333,000 after buying an additional 92,410 shares in the last quarter. Diversified Trust Co bought a new position in shares of Enanta Pharmaceuticals during the fourth quarter worth $159,000. Finally, Nisa Investment Advisors LLC grew its position in shares of Enanta Pharmaceuticals by 417.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,827 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 2,281 shares in the last quarter. Institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.